Loading clinical trials...
Loading clinical trials...
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
Conditions
Interventions
DCSZ11
Pembrolizumab
+2 more
Locations
35
United States
University of Alabama
Birmingham, Alabama, United States
Mayo Clinic
Phoenix, Arizona, United States
HonorHealth
Scottsdale, Arizona, United States
University of Colorado
Aurora, Colorado, United States
Sarah Cannon Research Institute Denver Healthone
Denver, Colorado, United States
Yale Cancer Center
New Haven, Connecticut, United States
Start Date
June 28, 2023
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2026
Last Updated
June 26, 2025
NCT06716138
NCT06307795
NCT05753722
NCT05581004
NCT07094113
NCT07205718
Lead Sponsor
DynamiCure Biotechnology
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions